One in 5 patients treated with adjuvant pembrolizumab experienced serious adverse events, so it remains important to weigh the risk vs benefits of the therapy for each individual patient. Overall survival data support adjuvant pembrolizumab after surgery as standard of care for select patients with clear cell renal cell carcinoma.
For patients with clear-cell renal cell carcinoma, adjuvant pembrolizumab is associated with a significant and clinically meaningful improvement in overall survival.
One in 5 patients treated with adjuvant pembrolizumab experienced serious adverse events, so it remains important to weigh the risk vs benefits of the therapy for each individual patient. Overall survival data support adjuvant pembrolizumab after surgery as standard of care for select patients with clear cell renal cell carcinoma.
How to Talk to Kids When a Parent Has Cancer time.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from time.com Daily Mail and Mail on Sunday newspapers.